
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA
December 18th, 2024
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA
December 18th, 2024
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s Linea DNA™ for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
May 13th, 2024
Applied DNA, Alphazyme Agreement for Scale-Up Linea™ RNAP
March 18th, 2024
APDN Announces JDA to Integrate Linea™ IVT Platform into Kudo Biotechnology’s mRNA Manufacturing Workflow
December 14th, 2023
APDN Announces Linea™ DNA Follow-On Order for Cancer Diagnostic Application
November 28th, 2023
APDN Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences
July 18th, 2023
APDN Acquires Spindle Biotech, Launches LineaIVT™ Platform
July 13th, 2023
APDN to Present at Upcoming Healthcare Investor Conference
June 8th, 2023
APDN Receives Largest Single Purchase Order for LinearDNA To Date
October 10th, 2022